Replimune Group (NASDAQ:REPL) Shares Gap Up - Here's Why

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) gapped up before the market opened on Thursday . The stock had previously closed at $8.46, but opened at $8.80. Replimune Group shares last traded at $8.67, with a volume of 531,190 shares trading hands.

Analyst Ratings Changes

A number of analysts have weighed in on the company. JPMorgan Chase & Co. boosted their price target on Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. BMO Capital Markets boosted their target price on Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a report on Wednesday, January 22nd. Finally, HC Wainwright increased their price target on Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, February 13th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $19.43.

Replimune Group Trading Down 2.6%

The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14. The company has a 50-day moving average price of $8.75 and a 200-day moving average price of $11.26. The company has a market capitalization of $634.53 million, a price-to-earnings ratio of -2.70 and a beta of 0.68.

Institutional Trading of Replimune Group

Hedge funds have recently added to or reduced their stakes in the business. Sterling Capital Management LLC increased its position in Replimune Group by 364.5% in the 4th quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock worth $26,000 after buying an additional 1,655 shares during the period. Graham Capital Management L.P. grew its stake in shares of Replimune Group by 6.1% in the fourth quarter. Graham Capital Management L.P. now owns 30,180 shares of the company's stock worth $365,000 after acquiring an additional 1,731 shares during the last quarter. Deutsche Bank AG grew its stake in shares of Replimune Group by 0.4% in the first quarter. Deutsche Bank AG now owns 563,701 shares of the company's stock worth $5,496,000 after acquiring an additional 2,140 shares during the last quarter. MetLife Investment Management LLC increased its position in Replimune Group by 7.2% during the fourth quarter. MetLife Investment Management LLC now owns 37,659 shares of the company's stock worth $456,000 after acquiring an additional 2,525 shares during the period. Finally, Arizona State Retirement System raised its stake in Replimune Group by 19.7% during the 1st quarter. Arizona State Retirement System now owns 15,439 shares of the company's stock valued at $151,000 after purchasing an additional 2,545 shares during the last quarter. Institutional investors own 92.53% of the company's stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.